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Background: Objective and reliable outcome measures to facilitate clinical trials of novel 
treatments for systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) are badly 
needed. Laser speckle contrast imaging (LSCI) and thermography are non-invasive measures 
of perfusion that show excellent potential. The purpose of this multi-centre study was to 
determine the reliability and validity of a hand cold challenge protocol using LSCI, standard 
thermography and low-cost mobile phone-based thermography. 
Methods: Patients with RP secondary to SSc were recruited from 6 UK tertiary-SSc centres 
and underwent cold challenge on 2 consecutive days. Changes in cutaneous 
perfusion/temperature at each visit were imaged simultaneously using LSCI, standard and 
mobile phone thermography. Measurements included area under reperfusion/rewarming 
curve (AUC) and maximum perfusion/rewarming (MAX). Test-retest reliability was assessed 
using intraclass correlation coefficients (ICC). Estimated latent correlations assessed 
convergent validity of LSCI and thermography. 
Results: 159 patients were recruited (84% female, 77% limited cutaneous, median age 63.3 
years). LSCI and standard thermography both had substantial reliability, ICCs (95%CI) for 
AUC were 0.67(0.54-0.76) and 0.68(0.58-0.80) respectively, and for MAX were 0.64(0.52-
0.75) and 0.72(0.64-0.81) respectively. Very high latent correlations (95% CI) were present 
for AUCs of LSCI and thermography [0.94(0.87-1.00)], and for AUCs of standard and mobile 
phone thermography [0.98(0.94-1.00)]. 
Conclusion: This is the first multi-centre study examining reliability and validity of cold 
challenge using LSCI and thermography in patients with SSc-related RP. LSCI and 
thermography demonstrated good potential as outcome measures. LSCI, standard and 
mobile phone thermography had very high convergent validity. 
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Systemic sclerosis (SSc)-related digital vasculopathy is painful and disabling, and has 
significant impact on quality of life. Raynaud's phenomenon (RP) occurs in most patients 
with SSc (96%) and is consistently the highest ranked symptom of SSc in terms of frequency 
and impact on daily function (1,2). In patients with SSc, RP often progresses to severe digital 
vasculopathy, with up to 50% of patients developing painful digital ulceration (3-11). 
Treatments are far from ideal and Cochrane and other reviews highlight the lack of evidence 
base for the treatment of both primary and SSc-related RP (12-15): one of the reasons for 
this is the lack of reliable outcome measures that are necessary to deliver successful clinical 
trials. Technological advances in laboratory measurements of blood flow (laser speckle 
contrast imaging [LSCI] and thermography [skin temperature- a pseudo measure of 
perfusion]) hold promise as objective measures (16,17). The Outcome Measures in 
Rheumatology (OMERACT) 6 report, describing the current status of outcome measure 
development for clinical trials in SSc, concluded that whether imaging techniques made the 
transition from research pathophysiology measurement techniques to outcome measures 
for RP was dependent upon ‘whether data are published or available to show their validity’ 
(18). The requirement for reliable outcome measures to facilitate highly powered clinical 
trials in SSc-related RP is now especially pertinent due to on-going novel drug developments 
(19-23). Whilst patient-reported outcome measures such as the Raynaud’s condition score 
(RCS(24)) are well suited for later, phase III studies, objective non-invasive imaging 
techniques would provide confirmatory testing to inform stop-go decision-making in earlier 
phase II studies.  
 
Our main aim was to determine whether LSCI and thermography, alongside a cold challenge 
of the hands, are sufficiently reliable and valid to allow their use as outcome measures in 
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multicentre clinical trials. Our primary objectives were to evaluate test-retest reliability and 
construct validity (25), which we defined as the ability of LSCI and thermography to measure 
important features of SSc-related digital vasculopathy. Our secondary objectives were to 
assess inter-observer reliability, and feasibility, of the techniques. Just prior to 
commencement of our study, mobile phone thermography came on the market as an 
imaging method, potentially offering a more cost-effective and portable alternative to LSCI 
and 'standard' thermography. Hence an additional secondary objective was to assess the 
utility of mobile phone thermography in comparison to standard thermography.  
 
METHODS 
Six UK tertiary-SSc centres took part in the study; individuals responsible for imaging and 
analysis attended a central training session prior to the start of recruitment; At least one 
person from each centre attended the training. 
 
Patients 
The study aimed to recruit 180 patients with SSc. Inclusion and exclusion criteria are listed in 
supplementary Table S1 and included current digital ulceration. The study was approved by 
Cambridgeshire and Hertfordshire NRES committee (15/EE/0083) and all patients gave 
written consent. Each visit took approximately one hour. All patients were recruited 
between 1/10/15 and 28/2/15 to minimise inter-individual variation related to season.  
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Imaging equipment   
An LSCI (FLPI-2 [Moor Instruments, Axminster, UK] Figures 1a and 2b (16,17)) was leased to 
each centre. Five of the six centres used their own thermal cameras (referred to as 
‘standard thermography’ Figure 1a, b and d (26)); a camera was leased to the sixth. A mobile 
phone/device-connectable thermography camera (FLIR One Figure 1a and 1c) and an Apple 
iPhone 5 was purchased for each centre along with all other cold challenge equipment (to 
minimise centre variation). To minimise differences between centres, equipment at each 
site was set-up according to strict guidelines for positioning to ensure images were taken in 
as similar manner as possible (angles/distances) and underwent a calibration protocol at the 
start and end of the study (carried out by a single person from the central site).. LSCI 
settings were adjusted for distance, frequency, duration, focus, intensity overlay, processing 
mode (high resolution), and colour image acquisition. Thermal cameras settings were 
adjusted for room temperature, distance to hands and skin emissivity. Mobile phone 
thermography settings were limited but set to matt. 
 
Cold challenge  
Patients were requested to wear light clothing and refrain from vigorous exercise, caffeine 
and alcohol for 4 hours prior to the assessment. Upon arrival patients were seated 
comfortably for 20 minutes and acclimatised; clinical research forms were completed. 
Immediately prior to the cold challenge, a baseline image of both hands (dorsal aspect) was 
taken with LSCI and both thermal cameras. As required for LSCI imaging, all images were 
acquired in low-lit rooms. The patient’s hands were placed on a black, thermally insulated 
surface (one metre away from the thermal cameras and 70cm (+/- 5cm) from the LSCI). 
Small sticky dots were used to mark the location of each finger at baseline. Both hands were 
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nitrile gloved and immersed to the metacarpophalangeal joints for 1 minute into cooled 
water; 2 standard containers at 15 ± 1°C (measured by calibrated thermometer) one on 
either side of the patient. After the cold challenge, gloves were removed and hands 
returned to their original position on the insulating surface, secured by double sided sticky 
tape to avoid movement between images. Reperfusion/rewarming after cold challenge was 
imaged simultaneously by LSCI at 15 frames per minute and thermography (at 4 frames per 
minute) for 15 minutes (i.e contemporaneous measurement for 15 minutes post cooling). 
Mobile phone thermography did not allow for continuous video images to be obtained from 
which data could be extracted and thus single images were taken at set time points; 
baseline, 0 and 15 minutes after cold challenge. At the end of the 15 minutes one extra 
image was taken for LSCI and standard thermography to allow the gradient of the last data 
point to be calculated; thus a total of 225 images/scans were obtained for LSCI, 61 for 
thermography and 3 for mobile phone thermography during the 15 minutes of 
measurement. Analysis was performed in Moor Instruments Laser Perfusion Imager 
software version 4.0 for LSCI, and Research IR max version 4.2, [FLIR, Sweden] for standard 
and mobile thermography. Patients completed an RCS (0-10) at each visit (‘RCS on the day’), 
measuring the severity and impact of their RP for that day (24). 
 
The cold challenge was repeated one day later (Day 2) as close as possible to the same time 
of day to minimise variation due to circadian rhythms (27). The repetition over 2 consecutive 
days (i.e. approximately 24 hours) minimised any variations within individuals over time 
(e.g. menstrual cycle effects) and seasonal variation in weather (28). Five centres had one 
observer, one centre had 2. Each examiner re-examined same subject on days one and two. 
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(for example at the central site one observer imaged 60 patients, twice, on consecutive 
days) Figure 2 shows the study design. 
 
Image analysis: summary measures of response 
Image analysis was carried out locally by an internal non-blinded observer at each centre. 
These were the same observers that had taken the images. Regions of interest (ROIs, Figures 
1b and 2b and c), were highlighted in the baseline (pre cold challenge) image and in 
sequential images for 15 minutes post cooling. The distal dorsal difference (DDD, 
measurement difference between dorsum and finger, (29,30) (with subscripted L, T or M for 
LCSI, thermography and mobile phone thermography respectively where applicable) was 
calculated for each finger at baseline. In the sequential images the ROIs were confined to 
the 8 distal phalanges. The area under the reperfusion/rewarming curve (AUC) for each 
finger was calculated manually, not by automation, (Figure 3 [standard thermography],3) 
from 61 post challenge images as well as the maximum blood flow/temperature after 
rewarming (MAX), and the gradient in the first 2 minutes (GRAD). Data were averaged for all 
fingers as in previous studies (16). For mobile phone thermography DDD was taken from the 
first of 3 images and AUC approximated by averaging over the latter two images. Analysis 
took less than one hour per participant, per visit.  
 
Saved images and ROI local analysis data were also analysed by the blinded central 
observer. Mobile phone thermography image analysis was carried out only at the central 
site. 
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Feasibility 
Feasibility was assessed at the end of the study by clinical scientist/technician opinion (ease 
of use and analysis 0-10 [0=difficult], preference of LCSI or thermography [standard or 
mobile] for acquiring and analysing images).   
Room temperature measurement 
A prerequisite of the cold challenge, and thus centre participation, was a temperature-
controlled room at each centre.  All measurements were taken in a temperature controlled 
room (aimed at 23 ± 2°C). Room temperatures were recorded with data monitors (TinyTag, 
Gemini Data Loggers, UK) to assess the impact of temperature on measurements, with an 
interest in examining whether reliability could be improved by achieving greater 
temperature control.  
 
Edge effects from LCSI 
It became apparent when the study began that the blood flow appeared to be lower at the 
edges of the LSCI images than in the centre. This implied that the distribution of the laser 
light across the hands was not equal, with less light incident towards the edges than at the 
centre of the image. If true then the consequence of this would be artificially lower value 
perfusion for little fingers (edge of image, Figure 4) compared to index fingers (centre of 
image) in the LSCI images. Thus this was investigated further as detailed below.  
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Statistical analysis  
Analysis was performed using R version 3.2.3 (31).  
Based upon a previous thermography study (16) 180 patients would allow us to estimate 
reliability to within 0.05. A full discussion of the sample size calculation and other aspects of 
the statistical analyses are provided in the supplementary material (extended statistical 
analysis).  
 
Test-Retest Reliability of the techniques: Intraclass correlation coefficients (ICCs) were 
obtained using linear mixed effects models with each summary measure included as a 
dependent variable and with centre as a fixed effect.  
 
Reliability between observers: The data over both visits for each patient were averaged and 
the resulting averages between central and centre-specific observer compared by 
calculating the difference and 95% CI for the paired means (Table S2). It is not possible to 
calculate a valid inter-observer ICC from this data, which would require at least some of the 
participants to have travelled to all sites for imaging and a large subset of images analysed 
by all observers (32). 
 
Validity of the techniques: Convergent validity (one aspect of construct validity) was 
assessed using bivariate linear mixed models including fixed centre terms and separate 
random patient intercepts for 1) LSCI and standard thermography and 2) standard and 
mobile thermography. We estimated the latent correlation (which would be equal to one if 
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the techniques measured the same construct). For clarity, the mathematical representation 
of this joint model is provided in the supplementary material [statistical analysis (protocol)].  
A post-hoc analysis was conducted where the responses to the RCS corresponding to the 
study day were related to the measurements, using linear mixed models. 
Feasibility: Descriptive statistics were used to summarise the feasibility data.  
Room temperature: The mean temperature for each patient visit was added to the mixed 
effects models for each summary measure. ICCs were recalculated, and compared with the 
previously calculated estimates.  
Edge effects: This was investigated in a post-hoc analysis by calculating the trend across 
fingers for LSCI measurements and comparing these to thermography. Linear mixed models 
were used to assess any linear trends in the measurements from the index finger to the 
little finger. Fingers were numbered.Finger-level summary measures of response were  then 
regressed on finger number for both LSCI and thermography; this linear approximation was 
crude but sufficient. Random intercept and slope terms were included to account for the 
fact that there was variation from patient to patient in these trends not attributable to the 
imaging techniques. Measurements were standardised prior to analysis, thereby allowing 
comparison to be made between LSCI and thermography.  
 
RESULTS 
159 patients were recruited (60 from the central centre, 16-20 from each of the others): 157 
(99%) fulfilled the 2013 American College Rheumatology/European League Against 
Rheumatology criteria (34); median age 63.3 IQR (53.8-69.5) years; 123 (77%) lcSSc; 
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duration since first non-Raynaud’s symptom 9.6 (4.5-17.4) years; 146 (93%) were on 
vasodilators (62 calcium channel blockers, 27 ACE inhibitors, 27 angiotensin II receptor 
antagonist, 22 Phosphodiesterase-5 inhibitor, 4 endothelin Receptor Antagonist, 1 Nitrates. 
35 were on one or more vasodilator); 4 (3%) had previously had finger surgical 
debridements; 5 (3%) had previously had amputations; 30 (19%) had experienced ulcers in 
the last year.  
Test-Retest Reliability of the techniques: There was at least moderate to substantial 
reliability for DDDL,M,T AUCL,T,M and MAXL,T. GRADL,T were fair to substantial (Table 1 (35)). A 
value of 0.7 could be considered high such that both MAX and AUC display strong 
convergence. Strength of reliability: 0.00 to 0.20 = slight; 0.21 to 0.40 = Fair; 0.41 to 0.60 = 
Moderate; 0.61 to 0.80 = Substantial; 0.81 to 1.00 = Almost perfect as per (33) although 
these classifications are to some extent arbitrary and should be treated as a rough guide.  
Reliability between observers: The data for each visit, observer and centre are displayed in 
Supplementary Table S2 and additionally at patient-level using ladder plots  (Figure S1). If 
the measures were perfectly reliable the subplot for each centre would look like two 
identical ladders (but it is not expected that the plots will be identical between centres). Our 
data suggest that there were systematic differences between the central observer and 
centre 2 (and possibly centre 3) in extracting data from LSCI images.  For thermography, 
agreement between the central and local observer was generally high for all centres, albeit 
with a large discrepancy for several patients for one of their visits. 
Validity of the techniques: The latent correlation (95% CI) for LSCI and thermography  (i.e. 
evidence that LCSI and standard thermography measure the same construct, in this case 
blood returning to the finger) was DDD: 0.65 (0.50 to 0.79); AUC: 0.94 (0.87 to 1.00) and 
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MAX: 0.87 (0.77 to 0.95); but GRAD only 0.52 (0.33 to 0.70), Table 1. High latent correlation 
is indicative of convergent validity. A value of 0.7 could be considered high such that both 
MAX and AUC display strong convergent validity. Correlation between mobile thermography 
and standard thermography was also very high; 0.98 (0.94 to 1.00) for AUC and 0.90 (0.79 to 
0.97) for DDD, Latent correlation between LSCI and FLIR was 0.86 (0.74 to 0.97) for AUC and 
0.49 (0.29 to 0.66) for DDD. (Table 1).  
With the exception of some weak evidence of decreasing DDDT with increasing RCS (-0.15 
DDDT for a one point increase in RCS, on average, SE = 0.07) we found no evidence of 
correlation between the summary measures and RCS. 
Feasibility: Standard thermography was deemed to be more feasible than LSCI (see 
discussion). The proportion of raters giving a score of 7 or above for ease of use (0=difficult–
10=easy) was 50%for LSCI; 75%for standard thermography and 38%for mobile phone 
thermography. Ease of analysis was rated as 7 or above by 25% for LSCI and 50%for 
standard thermography. The number of centres preferring LSCI to thermography was 1 for 
acquiring and 1 for analysing images; preferring standard thermography 3 (acquiring) and 4 
(analysing). The remaining centres showed no preference.  
Room temperature: When included as a covariate, temperature was not associated with any 
of the summary measures as measured by either LSCI or thermography. Additionally, the 
ICCs were not affected by the inclusion of temperature in the analysis. This does not mean 
that a regulated room temperature is not important but that small changes in temperature 
are acceptable (supplementary Table S3).  
Edge effects: Moving from the thumb to the little finger, all of the AUC, MAX and GRAD 
trends were in the opposite direction for the two modalities, with a decrease for LSCI and an 
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increase for thermography (supplementary Table S4). Both estimates for the DDD are 
positive, but this was attenuated for LSCI. This is consistent with an edge effect artificially 
producing lower values for the little fingers with LSCI. The cause of the edge effect was 
identified as the distribution of the light over the imaging area, due to LSCI being used at the 
upper limit of the suggested imaging distance in order to fit both hands into the imaging 
area. The data indicates that care must be taken to understand the variations over the field 
of view so that these can be accounted for; decreasing the field of view would minimise 
these results in future studies.  
 
DISCUSSION 
To date laser speckle imaging techniqu s and thermography have been insufficiently studied 
as outcome measures in clinical trials. Those studies in which they have been included show 
very little consistency in terms of protocol design (24, 36-38), choice of dynamic challenge 
and extracted outcome measures, making it difficult to compare results between studies or 
establish a standard protocol. The main finding of our study is that reliability of both LSCI 
and thermography were sufficiently high (AUC and MAX) for use as study outcome 
measures.  The reliability of MAXT was slightly superior to MAXL. Other than this, there were 
no substantive differences in reliability between the two techniques.  
 
AUCM and DDDM showed adequate reliability for use as outcome measures. Moreover, there 
was strong correlation between mobile phone and standard thermography data. The mobile 
phone thermography was added at a late stage in this project (since it had only just come on 
the market). Our reason for including it was primarily for feasibility assessment. While it is 
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clear that further work is required to validate mobile thermography, the performance in the 
present study is highly encouraging because as a low-cost tool it could potentially be readily 
available for widespread use amongst rheumatologists.   
 
Although not our primary objective, we examined differences between observers. 
Systematic differences between observers at different centres would not be particularly 
problematic for a multicentre randomised controlled trial (RCT), provided randomisation 
was stratified by centre. We note that this should be the default for any multicentre trial, 
since differences between centres may otherwise bias the estimated treatment effect. This 
is particularly true in small populations, since simple randomisation is less likely to produce 
balance within centres. Standardised training would reduce measurement variation across 
centres and centralised blinded extraction and analysis of LSCI data might also minimise 
variation by removing multi-observer differences in an RCT setting. Given the small sample 
size at each centre we are unable to determine whether truly systematic differences were 
observed. Ideally, a study to assess inter-observer reliability would involve participants 
having images analysed by all observers.   
 
Convergence between the techniques was shown to be very high for AUC and MAX 
(particularly for AUC). This provides evidence that the same underlying construct is being 
measured when using these summaries of response. Convergence appeared to be weaker 
(although still moderate) for DDD. Convergence was weakest for GRAD which may reflect a 
lag between tissue re-perfusion (measured with LSCI) being translated into skin re-warming 
(measured using thermography) during the 2 minutes immediately following cold challenge. 
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Since there is no gold standard to compare either imaging technique to, and we are 
comparing two techniques that measure perfusion by very different methods (skin 
temperature and a measure of red blood cell concentration and speed by light) it is possible 
to measure convergence between these techniques for validity (25). It would be unlikely for 
these two techniques to converge whilst also being poor measures since they would both 
have to be deficient in distinct but very specific ways so as to bring the erroneous 
observations into alignment. Therefore we can conclude in this instance that their 
convergence implies validity. 
 
The OMERACT review of 2003 (18) assessed the validity of several non-invasive techniques 
as possible objective outcome measures but none was deemed ready for use in clinical 
trials. These included nailfold capillaroscopy, a well-established diagnostic technique is now 
included in the diagnostic criteria (34) to differentiate primary and secondary Raynaud’s 
phenomenon. The microscopy technique allows visualisation of cutaneous capillaries at the 
nailbed and identification of structural change characteristic of SS.  This is not a substitute 
though for functional measures of flow (although functional flow and oxygenation have 
recently been reported). Plethysmography allows the change in vascular volume to be 
measured (i.e. detection of a pulse) in combination with cold challenge. The technique can 
measure full fields in the same ways as laser speckle but remains unvalidated. There was no 
relationship between the summary measures and the RCS on the day of the study visits, for 
either LSCI or thermography. Patient-centred outcome measures are crucial for evaluating 
the effectiveness (rather than just the efficacy) of treatments. However, patient-centred 
outcomes often comprise more 'noise' compared to more objective measures of response, 
and therefore necessitate larger sample sizes to ensure adequate power in clinical trials. For 
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small populations, there is therefore a tension between direct relevance to patients and 
feasibility of conducting a trial. One solution may be to power studies on the basis of 
objective measures such as those considered here, and to additionally (and consistently) 
report patient-centred outcomes to facilitate an eventual meta-analysis. Another might be 
to seek confirmatory evidence for the vasodilatory potential of candidate interventions 
using objective measures before proceeding to larger phase 3 clinical trials 
The relationship between two measures is limited by the reliability of each (39). While 
relative stability of RCS has been observed between baseline and follow-up in clinical 
trials/studies (38,40), there has been little work formally assessing its intra-individual 
reliability.  
Regarding feasibility, comments were made regarding LSCI and its sensitivity to movement, 
vibrations and lighting, indicating the importance of environmental conditions. For the 
mobile phone thermography, present limitations include battery life (LSCI and 
thermography were mains/long-life battery powered), fixed focussing distance and lack of 
analysis for video images, as well as mounting difficulties; however, if the mobile and 
standard thermography correlation can be replicated in future studies, these limitations 
may be acceptable in light of the lower cost and ambulatory (convenient) nature of the 
technique. When comparing feasibility of LSCI versus thermography, it should be noted that 
most centres were familiar with thermography but not LCSI, and that this may have 
influenced assessment of feasibility.  
 
One limitation of the study was that we did not recruit the planned number of participants, 
due to a seventh centre not participating as planned. However, the study was designed to 
be robust to under-recruitment. Although the 95% CIs for our estimates are wider than they 
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would have been had the target been met, we were still able to demonstrate good enough 
reliability and convergent validity of AUC and MAX, to observe differences indicative that 
that the performance of DDD was weaker, and to show that the performance of GRAD was 
relatively poor.  
 
In conclusion, our design was relatively pragmatic, with the aim of establishing the 
performance of the different techniques as they would be employed in a multicentre clinical 
trial. Our study successfully established a working group of tertiary-SSc centres, and 
together the group developed a consensus calibration and cold challenge protocol. The 
summary measures AUC and MAX both displayed good reliability and strong convergent 
validity. There was a possible advantage of thermography in relation to the reliability of 
MAX, although this was not definitive. We found evidence of edge effects when using LSCI 
although our summary measures appeared to be quite robust to these in relation to 
reliability, perhaps suggesting that these effects were fairly consistent (methods and results 
discussed in supplementary data). The study has also confirmed that small variations in 
room temperature are acceptable and that, subject to further validation, mobile phone 
cameras may be a suitable, affordable, highly portable alternative to more expensive 
standard imaging equipment (although mobile phones are battery operated and with less 
functionality [at present] than larger thermal cameras). The mobile phone data obtained in 
this study will facilitate the design of future validation studies into mobile phone 
thermography-derived outcome measures. Although the design precluded formal 
assessment of inter-observer reliability there was a suggestion of systematic differences 
between the central observer and observers at some centres, highlighting the importance of 
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image analysis training and potentially a role for centralised or automated image analysis. 
For multicentre RCTs, we would also recommend that where possible/appropriate, 
randomisation be stratified by centre to balance any centre effects and prevent bias.  
In summary LSCI and thermography should now be incorporated as secondary outcomes in 
upcoming treatment efficacy trials. This will allow an assessment of responsiveness to 
treatment as well as longitudinal validity. The present study leads us to recommend the 
summary measures AUC and MAX, measured using both thermography and LSCI (but 
especially using thermography), as suitable outcome measures for RCTs in SSc-related RP. 
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LEGENDS  
Figure 1: a) Photograph of the imaging equipment set-up to allow simultaneous imaging, showing 
LSCI and standard and mobile thermography; b) Baseline image of hands taken with standard 
thermography showing distal dorsal difference (DDD) regions of interest (ROI), fingers cooler than 
dorsum; c) An example of hands imaged by mobile phone thermography at 0 mins post cold 
challenge, fingers cooler than dorsum (scale unavailable for image due to software); d) An example 
of hands (same subject as in b)) imaged by the standard thermal camera undergoing rewarming 
(from left to right, 0 mins after cooling, 7.5 mins and 15 mins), scale to the right 20-37 
o
C refers to b 
and d. 
 
Figure 2: Study design demonstrating images taken contribute to convergent validity, test-retest and 
intra-observer differences.  
 
Figure 3: Example of a rewarming curve (for one hand measured with standard thermography), 
temperature vs rewarming time, one line for each finger (ROI as per b)). Annotation: area under the 
curve (AUC) bounded by green rewarming line (for middle finger) and 2 green dotted lines, 
maximum temperature (MAX), shown with red dotted line and arrow and gradient in the first 2 mins 
(GRAD) shown in enlarged box, represented by red dotted line for index finger (red rewarming 
curve). 
 
Figure 4: a) LSCI reperfusion graphs (perfusion [flux (proportional to the product of the average 
speed of the blood cells and their number concentration, expressed in arbitrary ‘perfusion units’), vs. 
time]) for 8 digits (ROI 1-4 and 6-9 in 2b) and 2 dorsa (ROI 5 and 10;  b) Example flux (ie perfusion 
map) image showing ROIs marked (see Figure 1); c) photographic image of hands showing ROIs. 
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Figure 2: Study design demonstrating images taken contribute to convergent validity, test-retest and intra-
observer differences.  
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Figure 3: Example of a rewarming curve (for one hand measured with standard thermography), temperature 
vs rewarming time, one line for each finger (ROI as per b)). Annotation: area under the curve (AUC) 
bounded by green rewarming line (for middle finger) and 2 green dotted lines, maximum temperature 
(MAX), shown with red dotted line and arrow and gradient in the first 2 mins (GRAD) shown in enlarged box, 
represented by red dott d line for index finger (red rewarming curve).  
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Figure 4: a) LSCI reperfusion graphs (perfusion [flux (proportional to the product of the average speed of 
the blood cells and their number concentration, expressed in arbitrary ‘perfusion units’), vs. time]) for 8 
digits (ROI 1-4 and 6-9 in 2b) and 2 dorsa (ROI 5 and 10;  b) Example flux (ie perfusion map) image 
showing ROIs marked (see Figure 1); c) photographic image of hands showing ROIs.  
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Table 1: Reliability and validity of Laser speckle contrast imaging (LCSI) and thermography 
(standard and mobile phone) in patients with SSc-related RP.  
 Test-retest reliability  
[ICCs and 95% confidence intervals 
(CIs)] 
Comparison of 
reliability 
between LSCI 
and standard 
thermography 
[difference in 
reliability] 
Validity 
[estimated latent correlation 
between LSCI and standard 
thermography and between 
standard and mobile phone 
thermography] 
Summary 
measure 
 
LSCI 
(N=1
59) 
Standard 
thermography 
(N=159) 
Mobile phone 
thermography 
(N=141**) 
Difference† in 
ICCs: LSCI 
minus 
Thermography 
Correlation of 
LCSI and 
standard 
thermography  
Correlation of 
standard and 
mobile phone 
thermography 
Distal dorsal 
difference 
DDD 
0.67 
(0.56 
to 
0.77) 
0.58 (0.43 to 
0.71) 
0.61 (0.51 to 
0.73) 
0.08 (-0.05 to 
0.25) 
0.65 (0.50 to 
0.79) 
 0.90 (0.79 to 
0.97) 
Area under 
reperfusion 
/rewarming 
curve 
Log(AUC) 
0.67 
(0.54 
to 
0.76) 
0.68 (0.58 to 
0.80) 
0.61 (0.51 to 
0.72)* 
-0.01 (-0.17 to 
0.11) 
0.94 (0.87 to 
1.00) 
0.98 (0.94 to 
1.00) 
maximum 
perfusion 
/temperature 
Log (MAX) 
0.64 
(0.52 
to 
0.75) 
0.72 (0.64 to 
0.81) 
NA 
-0.09 (-0.21 to 
0.03) 
0.87 (0.77 to 
0.95) 
NA 
gradient over 
first 2 
0.46 
(0.40 
0.56 (0.40 to NA -0.09 (-0.24 to 0.52 (0.33 to NA 
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N=number of participants. Data have been averaged over 8 digits. 
*AUC for mobile phone approximated by mean of 2 frames, post cold challenge);  
**141 data sets were available for the mobile phone thermography (n=18 missing due to 
technical fault at two centres).  
† Differences between the point estimates for LSCI and standard thermography (test-
reliability columns, 3 and 4). 
minutes 
GRAD 
to 
0.69) 
0.74) 0.18) 0.70) 
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Supplementary Table S1: Inclusion and exclusion criteria. 
Inclusion criteria Exclusion criteria 
Signed informed consent. Primary RP or secondary RP due to aetiology 
other than SSc. 
RP defined as a history of digital cold 
sensitivity associated with colour 
changes (cyanosis and pallor). SSc as 
diagnosed by an experienced 
rheumatologist and fulfilling either 
the American College of 
Rheumatology criteria for SSc (32) or 
the criteria for early disease as 
defined by LeRoy and Medsger et al 
(40). 
Inability to undergo LSCI or thermography due 
to active digital ulcers or inability to extend 
fingers sufficiently or any other skin features 
that would lead to. 
Male and female patients aged ≥ 18 
years at screening. 
 
Any significant organ involvement or 
concomitant condition which, in the opinion 
of the investigator, would make in unwise for 
the patient to participate in the study. 
Stable vasoactive medication: doses 
stable for at least 1 month prior to 
Visit 1 and until Visit 2.  
Any disorder limiting the ability to provide 
informed consent or to comply with study 
requirements. 
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 Diabetes mellitus which affects the 
microcirculation. 
 Females who were breast feeding or 
pregnant. 
 Smokers; the use of nicotine patches was not 
allowed as these cause vasoconstriction. 
 Change of vasoactive medication within 1 
month prior to Visit 1 or planned change of 
medication between the study visit dates. 
 Treatment with prostacyclin (epoprostenol) or 
prostacyclin analogs (i.e., iloprost, 
treprostinil) within 1 month prior to Visit 1. 
 Local treatment (digits) with botulinum toxin 
type A within 1 month prior to Visit 1. 
 Topical administration of nitrates within 1 
week prior to Visit 1. 
 Treatment with vasoconstrictive drugs (e.g., 
ergot derivatives, triptans) within 1 week 
prior to Visit 1. 
 Surgical sympathectomy of digit within 3 
months prior to Visit 1. 
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Supplementary Table S2: Summary measures of responses to cold challenge comparison of 
data taken by central and centre-specific observers for LCSI and standard thermography. 
 
Central observer vs centre specific observer 
Centre DDD Log(AUC ) Log(MAX) GRAD 
 LSCI 
(arb 
PU) 
Standard 
therm. 
(
o
C) 
LSCI (arb 
PU*time) 
Standard 
therm. 
(
o
C*time) 
LSCI 
(arb 
PU) 
Standard 
therm. 
(
o
C) 
LSCI (arb 
PU/time) 
Standard 
therm. 
(
o
C/time) 
Centre 
2 
9.0 (-
30.0 to 
47.8) 
0.02 (-
0.92 to  
0.96) 
0.09 (-
0.35 to 
0.53) 
0.02 (-0.07 
to 0.10) 
0.10 (-
0.19 to 
0.39) 
0.00(-
0.09 to 
0.08) 
-3.36 (-
16.2 to 
9.43) 
-0.08(-
0.37 to 
0.22) 
Centre 
3 
48.6 
(17.3 to 
79.9) 
0.18 (-
0.46 to 
0.82) 
0.25 (-
0.08 to 
0.58) 
0.00 (-0.06 
to 0.07) 
0.22 (-
0.04 to 
0.49) 
0.01(-
0.05to 
0.08) 
1.29(-
5.39 to 
7.98) 
-0.07(-
0.46 to 
0.31) 
Centre 
4 
-15.7 
(48.0 to 
63.7) 
0.29(-
0.76 to 
1.34) 
-0.15(-
0.56 to 
0.25) 
0.00(-
0.07to 
0.06) 
-0.12(-
0.47 to 
0.23) 
0.00(-
0.07 to 
0.07) 
-0.62(-
6.93 to 
5.69) 
0.05(-
0.12 to 
0.23) 
Centre 
5 
-12.7(-
51.6 to 
26.2) 
0.11(-
0.84 to 
1.05) 
-0.03(-
0.33 to 
0.28) 
0.00(-0.06 
to 0.07) 
-0.01(-
0.25 to 
0.23) 
0.00(-
0.07to 
0.08) 
-2.56(-
17.9 to 
12.8) 
-0.06(-
0.36 to 
0.24) 
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Centre 
6 
-5.5(-
21.6 to 
10.5) 
0.06(-
0.60 to 
0.73) 
-0.03(-
0.23 to 
0.18) 
0.01(-0.06 
to 0.07) 
-0.02(-
0.18 to 
0.15) 
0.01(-
0.06 to 
0.08) 
-0.32(-
5.07 to 
4.43) 
-0.11(-
0.48 to 
0.26) 
For comparison of data between observers: Differences in paired means (95% CI), calculated 
as central minus centre-specific. Measurements taken by a central blinded observer were 
compared to the corresponding measurements taken at each centre. The data over both 
visits for each patient were averaged and the resulting averages between the central 
observer and the centre-specific observer compared by plotting the data and calculating the 
difference and 95% CI for the paired means. Centre 1 is excluded from the analysis as there 
were multiple observers at this site. The exploratory nature of these supplementary 
analyses should be emphasized.  
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Supplementary Table S3: Room temperature data for each centre  
 
Centre One Two  Three Four Five Six 
Room 
temperature 
(
o
C)  
21.9  
21.6 to 
22.3 
20.4 to 
22.9 
23.6 
23.5 to 
23.7 
23.0 to 
24.0 
25.3 
24.4 to 
24.1 
22.6 to 
25.6 
23.9 
23.6 to 
24.1 
22.6 to 
25.6 
23.2 
23.0 to 23.5 
21.3 to 24.5 
23.3 
22.3 to 24.0 
20.2 to 26.9 
Summary of temperatures per patient visit (data taken over 45 minutes) at each of six 
centres. Median, interquartile range, range.  
.  
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Supplementary Table S4: Post hoc analysis of the edge effect observed for LSCI  
 
Summary Measure  LSCI Thermography 
Log(AUC) -0.17(0.02) 0.07 (0.01) 
DDD -0.21 (0.02) -0.01 (0.02) 
Max -0.19 (0.02) 0.07 (0.01) 
Gradient -0.07 (0.02) 0.04 (0.01) 
Estimated trends from index to little fingers, standard error (SEs) from linear mixed models. 
Units are standard deviations. Positive (negative) trends correspond to increases (decreases) 
moving across the fingers, with larger values indicating a stronger trend. 
Rows show summary measures: Mean (SD); Distal dorsal difference (DDD), area under the 
reperfusion or rewarming curve (AUC), maximum perfusion or temperature (MAX) and the 
gradient over the first 2 minutes (GRAD) have been averaged over 8 digits.  
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a) 
b) 
Supplementary Figure 1 (S1): Ladder plots showing patient-level summary measures of response measured at each 
measurement site (first point in each linked pair of points) and again by a universal rater (second point in each 
linked pair of points). Measurements are shown for each study visit and for a) LSCI and b) thermography.   
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Supplementary data:  
Expansion of statistical analysis of the data 
Justification of sample size: The sample size was selected both to estimate reliability 
precisely and to demonstrate substantial levels of reliability for thermography in the event 
that this reflected the actual performance of the technique. A reliability estimate for LSCI 
was not available, although Murray et al. [22] estimated the reliability of laser Doppler to be 
0.92. If LSCI were similar, we would obtain a lower 95% confidence limit of 0.89, again 
demonstrating strong reliability. In the event that the ICCs of the techniques were 
considerably lower than expected, a sample size of 180 would still allow estimation of the 
ICCs to a good degree of precision. For instance, if the ICC was as low as 0.65, then 180 
patients would allow a 95% confidence interval of overall width 0.17 to be calculated. The 
interval would then be 0.56 to 0.73. The inference of the study would then be that reliability 
of the measurement was ‘moderate’ to ‘substantial’. The target sample size was quite 
robust to substantial under recruitment. For example, we calculated that, on the basis of 
the figures presented above, a sample size of 120 would result in 95% CIs for thermography 
and LSCI of overall width 0.13 and 0.06 respectively, which would still represent a good level 
of precision. 
 
Reliability of the techniques: A fixed effect corresponding to each centre in the study and a 
patient-specific random intercept were included in the linear mixed effects models. In order 
to calculate 95% confidence intervals (CIs) for the ICCs a nonparametric bootstrap 
procedure was performed. In order to compare the reliability of summary measures 
obtained using LSCI compared to thermography, the difference in ICCs (with bootstrapped 
95% CIs) were calculated. AUC and MAX were log transformed due to skewed data prior to 
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modelling. Data from Mobile phone thermography were collected differently and therefore 
did not lend themselves to calculating all of the summary measures calculated using LSCI 
and standard thermography. The mean value and the mean DDD were calculated across 
eight fingers for each patient for each visit (the former a summary measure approximating 
AUC), and their reliability across visits was computed.  
 
Reliability between observers: Measurements taken by a central blinded observer were 
compared to the corresponding measurements taken at each centre. It is not be possible to 
calculate a valid inter-observer ICC from this data, which would require at least some of the 
participants to be measured by all of the observers. Without this, the patient-by-observer 
interaction is not identified [30]. One centre was excluded from this analysis as several 
observers analysed the images. The exploratory nature of these supplementary analyses 
should be emphasized.  
 
Mathematical representation of the model: Taking one summary measure at a time, for 
patient  we have one measurement and one replicate obtained using LSCI ( and ) and 
one using thermography (  and ). 
For  = 1,2  and  = 1,… ,  we model 
 =  +	 +  +   
 = 	 +	 +  +	  
~(0,  !) , ~(0,  #) and $% ~&' ($
0
0% , )
*+ ,*+*-
,*+*- *- ./ 
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The parameter , represents the latent correlation between the two techniques, having 
separated out the variability due to measurement error. This would be 1 if the techniques 
were measuring the same underlying construct, and provides evidence of the construct 
validity of the techniques. 
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Background: Objective and reliable outcome measures to facilitate clinical trials of novel 
treatments for systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) are badly 
needed. Laser speckle contrast imaging (LSCI) and thermography are non-invasive measures 
of perfusion that show excellent potential. The purpose of this multi-centre study was to 
determine the reliability and validity of a hand cold challenge protocol using LSCI, standard 
thermography and low-cost mobile phone-based thermography. 
Methods: Patients with RP secondary to SSc were recruited from 6 UK tertiary-SSc centres 
and underwent cold challenge on 2 consecutive days. Changes in cutaneous 
perfusion/temperature at each visit were imaged simultaneously using LSCI, standard and 
mobile phone thermography. Measurements included area under reperfusion/rewarming 
curve (AUC) and maximum perfusion/rewarming (MAX). Test-retest reliability was assessed 
using intraclass correlation coefficients (ICC). Estimated latent correlations assessed 
convergent validity of LSCI and thermography. 
Results: 159 patients were recruited (84% female, 77% limited cutaneous, median age 63.3 
years). LSCI and standard thermography both had substantial reliability, ICCs (95%CI) for 
AUC were 0.67(0.54-0.76) and 0.68(0.58-0.80) respectively, and for MAX were 0.64(0.52-
0.75) and 0.72(0.64-0.81) respectively. Very high latent correlations (95% CI) were present 
for AUCs of LSCI and thermography [0.94(0.87-1.00)], and for AUCs of standard and mobile 
phone thermography [0.98(0.94-1.00)]. 
Conclusion: This is the first multi-centre study examining reliability and validity of cold 
challenge using LSCI and thermography in patients with SSc-related RP. LSCI and 
thermography demonstrated good potential as outcome measures. LSCI, standard and 
mobile phone thermography had very high convergent validity. 
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Systemic sclerosis (SSc)-related digital vasculopathy is painful and disabling, and has 
significant impact on quality of life. Raynaud's phenomenon (RP) occurs in most patients 
with SSc (96%) and is consistently the highest ranked symptom of SSc in terms of frequency 
and impact on daily function (1,2). In patients with SSc, RP often progresses to severe digital 
vasculopathy, with up to 50% of patients developing painful digital ulceration (3-11). 
Treatments are far from ideal and Cochrane and other reviews highlight the lack of evidence 
base for the treatment of both primary and SSc-related RP (12-15): one of the reasons for 
this is the lack of reliable outcome measures that are necessary to deliver successful clinical 
trials. Technological advances in laboratory measurements of blood flow (laser speckle 
contrast imaging [LSCI] and thermography [skin temperature- a pseudo measure of 
perfusion]) hold promise as objective measures (16,17). The Outcome Measures in 
Rheumatology (OMERACT) 6 report, describing the current status of outcome measure 
development for clinical trials in SSc, concluded that whether imaging techniques made the 
transition from research pathophysiology measurement techniques to outcome measures 
for RP was dependent upon ‘whether data are published or available to show their validity’ 
(18). The requirement for reliable outcome measures to facilitate highly powered clinical 
trials in SSc-related RP is now especially pertinent due to on-going novel drug developments 
(19-23). Whilst patient-reported outcome measures such as the Raynaud’s condition score 
(RCS(24)) are well suited for later, phase III studies, objective non-invasive imaging 
techniques would provide confirmatory testing to inform stop-go decision-making in earlier 
phase II studies.  
 
Our main aim was to determine whether LSCI and thermography, alongside a cold challenge 
of the hands, are sufficiently reliable and valid to allow their use as outcome measures in 
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multicentre clinical trials. Our primary objectives were to evaluate test-retest reliability and 
construct validity (25), which we defined as the ability of LSCI and thermography to measure 
important features of SSc-related digital vasculopathy. Our secondary objectives were to 
assess inter-observer reliability, and feasibility, of the techniques. Just prior to 
commencement of our study, mobile phone thermography came on the market as an 
imaging method, potentially offering a more cost-effective and portable alternative to LSCI 
and 'standard' thermography. Hence an additional secondary objective was to assess the 
utility of mobile phone thermography in comparison to standard thermography.  
 
METHODS 
Six UK tertiary-SSc centres took part in the study; individuals responsible for imaging and 
analysis attended a central training session prior to the start of recruitment; At least one 
person from each centre attended the training. 
 
Patients 
The study aimed to recruit 180 patients with SSc. Inclusion and exclusion criteria are listed in 
supplementary Table S1 and included current digital ulceration. The study was approved by 
Cambridgeshire and Hertfordshire NRES committee (15/EE/0083) and all patients gave 
written consent. Each visit took approximately one hour. All patients were recruited 
between 1/10/15 and 28/2/15 to minimise inter-individual variation related to season.  
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Imaging equipment   
An LSCI (FLPI-2 [Moor Instruments, Axminster, UK] Figures 1a and 2b (16,17)) was leased to 
each centre. Five of the six centres used their own thermal cameras (referred to as 
‘standard thermography’ Figure 1a, b and d (26)); a camera was leased to the sixth. A mobile 
phone/device-connectable thermography camera (FLIR One Figure 1a and 1c) and an Apple 
iPhone 5 was purchased for each centre along with all other cold challenge equipment (to 
minimise centre variation). To minimise differences between centres, equipment at each 
site was set-up according to strict guidelines for positioning to ensure images were taken in 
as similar manner as possible (angles/distances) and underwent a calibration protocol at the 
start and end of the study (carried out by a single person from the central site).. LSCI 
settings were adjusted for distance, frequency, duration, focus, intensity overlay, processing 
mode (high resolution), and colour image acquisition. Thermal cameras settings were 
adjusted for room temperature, distance to hands and skin emissivity. Mobile phone 
thermography settings were limited but set to matt. 
 
Cold challenge  
Patients were requested to wear light clothing and refrain from vigorous exercise, caffeine 
and alcohol for 4 hours prior to the assessment. Upon arrival patients were seated 
comfortably for 20 minutes and acclimatised; clinical research forms were completed. 
Immediately prior to the cold challenge, a baseline image of both hands (dorsal aspect) was 
taken with LSCI and both thermal cameras. As required for LSCI imaging, all images were 
acquired in low-lit rooms. The patient’s hands were placed on a black, thermally insulated 
surface (one metre away from the thermal cameras and 70cm (+/- 5cm) from the LSCI). 
Small sticky dots were used to mark the location of each finger at baseline. Both hands were 
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nitrile gloved and immersed to the metacarpophalangeal joints for 1 minute into cooled 
water; 2 standard containers at 15 ± 1°C (measured by calibrated thermometer) one on 
either side of the patient. After the cold challenge, gloves were removed and hands 
returned to their original position on the insulating surface, secured by double sided sticky 
tape to avoid movement between images. Reperfusion/rewarming after cold challenge was 
imaged simultaneously by LSCI at 15 frames per minute and thermography (at 4 frames per 
minute) for 15 minutes (i.e contemporaneous measurement for 15 minutes post cooling). 
Mobile phone thermography did not allow for continuous video images to be obtained from 
which data could be extracted and thus single images were taken at set time points; 
baseline, 0 and 15 minutes after cold challenge. At the end of the 15 minutes one extra 
image was taken for LSCI and standard thermography to allow the gradient of the last data 
point to be calculated; thus a total of 225 images/scans were obtained for LSCI, 61 for 
thermography and 3 for mobile phone thermography during the 15 minutes of 
measurement. Analysis was performed in Moor Instruments Laser Perfusion Imager 
software version 4.0 for LSCI, and Research IR max version 4.2, [FLIR, Sweden] for standard 
and mobile thermography. Patients completed an RCS (0-10) at each visit (‘RCS on the day’), 
measuring the severity and impact of their RP for that day (24). 
 
The cold challenge was repeated one day later (Day 2) as close as possible to the same time 
of day to minimise variation due to circadian rhythms (27). The repetition over 2 consecutive 
days (i.e. approximately 24 hours) minimised any variations within individuals over time 
(e.g. menstrual cycle effects) and seasonal variation in weather (28). Five centres had one 
observer, one centre had 2. Each examiner re-examined same subject on days one and two. 
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(for example at the central site one observer imaged 60 patients, twice, on consecutive 
days) Figure 2 shows the study design. 
 
Image analysis: summary measures of response 
Image analysis was carried out locally by an internal non-blinded observer at each centre. 
These were the same observers that had taken the images. Regions of interest (ROIs, Figures 
1b and 2b and c), were highlighted in the baseline (pre cold challenge) image and in 
sequential images for 15 minutes post cooling. The distal dorsal difference (DDD, 
measurement difference between dorsum and finger, (29,30) (with subscripted L, T or M for 
LCSI, thermography and mobile phone thermography respectively where applicable) was 
calculated for each finger at baseline. In the sequential images the ROIs were confined to 
the 8 distal phalanges. The area under the reperfusion/rewarming curve (AUC) for each 
finger was calculated manually, not by automation, (Figure 3 [standard thermography],3) 
from 61 post challenge images as well as the maximum blood flow/temperature after 
rewarming (MAX), and the gradient in the first 2 minutes (GRAD). Data were averaged for all 
fingers as in previous studies (16). For mobile phone thermography DDD was taken from the 
first of 3 images and AUC approximated by averaging over the latter two images. Analysis 
took less than one hour per participant, per visit.  
 
Saved images and ROI local analysis data were also analysed by the blinded central 
observer. Mobile phone thermography image analysis was carried out only at the central 
site. 
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Feasibility 
Feasibility was assessed at the end of the study by clinical scientist/technician opinion (ease 
of use and analysis 0-10 [0=difficult], preference of LCSI or thermography [standard or 
mobile] for acquiring and analysing images).   
Room temperature measurement 
A prerequisite of the cold challenge, and thus centre participation, was a temperature-
controlled room at each centre.  All measurements were taken in a temperature controlled 
room (aimed at 23 ± 2°C). Room temperatures were recorded with data monitors (TinyTag, 
Gemini Data Loggers, UK) to assess the impact of temperature on measurements, with an 
interest in examining whether reliability could be improved by achieving greater 
temperature control.  
 
Edge effects from LCSI 
It became apparent when the study began that the blood flow appeared to be lower at the 
edges of the LSCI images than in the centre. This implied that the distribution of the laser 
light across the hands was not equal, with less light incident towards the edges than at the 
centre of the image. If true then the consequence of this would be artificially lower value 
perfusion for little fingers (edge of image, Figure 4) compared to index fingers (centre of 
image) in the LSCI images. Thus this was investigated further as detailed below.  
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Statistical analysis  
Analysis was performed using R version 3.2.3 (31).  
Based upon a previous thermography study (16) 180 patients would allow us to estimate 
reliability to within 0.05. A full discussion of the sample size calculation and other aspects of 
the statistical analyses are provided in the supplementary material (extended statistical 
analysis).  
 
Test-Retest Reliability of the techniques: Intraclass correlation coefficients (ICCs) were 
obtained using linear mixed effects models with each summary measure included as a 
dependent variable and with centre as a fixed effect.  
 
Reliability between observers: The data over both visits for each patient were averaged and 
the resulting averages between central and centre-specific observer compared by 
calculating the difference and 95% CI for the paired means (Table S2). It is not possible to 
calculate a valid inter-observer ICC from this data, which would require at least some of the 
participants to have travelled to all sites for imaging and a large subset of images analysed 
by all observers (32). 
 
Validity of the techniques: Convergent validity (one aspect of construct validity) was 
assessed using bivariate linear mixed models including fixed centre terms and separate 
random patient intercepts for 1) LSCI and standard thermography and 2) standard and 
mobile thermography. We estimated the latent correlation (which would be equal to one if 
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the techniques measured the same construct). For clarity, the mathematical representation 
of this joint model is provided in the supplementary material [statistical analysis (protocol)].  
A post-hoc analysis was conducted where the responses to the RCS corresponding to the 
study day were related to the measurements, using linear mixed models. 
Feasibility: Descriptive statistics were used to summarise the feasibility data.  
Room temperature: The mean temperature for each patient visit was added to the mixed 
effects models for each summary measure. ICCs were recalculated, and compared with the 
previously calculated estimates.  
Edge effects: This was investigated in a post-hoc analysis by calculating the trend across 
fingers for LSCI measurements and comparing these to thermography. Linear mixed models 
were used to assess any linear trends in the measurements from the index finger to the 
little finger. Fingers were numbered.Finger-level summary measures of response were  then 
regressed on finger number for both LSCI and thermography; this linear approximation was 
crude but sufficient. Random intercept and slope terms were included to account for the 
fact that there was variation from patient to patient in these trends not attributable to the 
imaging techniques. Measurements were standardised prior to analysis, thereby allowing 
comparison to be made between LSCI and thermography.  
 
RESULTS 
159 patients were recruited (60 from the central centre, 16-20 from each of the others): 157 
(99%) fulfilled the 2013 American College Rheumatology/European League Against 
Rheumatology criteria (34); median age 63.3 IQR (53.8-69.5) years; 123 (77%) lcSSc; 
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duration since first non-Raynaud’s symptom 9.6 (4.5-17.4) years; 146 (93%) were on 
vasodilators (62 calcium channel blockers, 27 ACE inhibitors, 27 angiotensin II receptor 
antagonist, 22 Phosphodiesterase-5 inhibitor, 4 endothelin Receptor Antagonist, 1 Nitrates. 
35 were on one or more vasodilator); 4 (3%) had previously had finger surgical 
debridements; 5 (3%) had previously had amputations; 30 (19%) had experienced ulcers in 
the last year.  
Test-Retest Reliability of the techniques: There was at least moderate to substantial 
reliability for DDDL,M,T AUCL,T,M and MAXL,T. GRADL,T were fair to substantial (Table 1 (35)). A 
value of 0.7 could be considered high such that both MAX and AUC display strong 
convergence. Strength of reliability: 0.00 to 0.20 = slight; 0.21 to 0.40 = Fair; 0.41 to 0.60 = 
Moderate; 0.61 to 0.80 = Substantial; 0.81 to 1.00 = Almost perfect as per (33) although 
these classifications are to some extent arbitrary and should be treated as a rough guide.  
Summary measures of responses to cold challenge obtained on days 1 and 2 at each centre 
for LCSI and thermography are shown in Table 2.  
Reliability between observers: The data for each visit, observer and centre are displayed in 
Supplementary Table S2 and additionally at patient-level using ladder plots  (Figure S1). If 
the measures were perfectly reliable the subplot for each centre would look like two 
identical ladders (but it is not expected that the plots will be identical between centres). Our 
data suggest that there were systematic differences between the central observer and 
centre 2 (and possibly centre 3) in extracting data from LSCI images.  For thermography, 
agreement between the central and local observer was generally high for all centres, albeit 
with a large discrepancy for several patients for one of their visits. 
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Validity of the techniques: The latent correlation (95% CI) for LSCI and thermography  (i.e. 
evidence that LCSI and standard thermography measure the same construct, in this case 
blood returning to the finger) was DDD: 0.65 (0.50 to 0.79); AUC: 0.94 (0.87 to 1.00) and 
MAX: 0.87 (0.77 to 0.95); but GRAD only 0.52 (0.33 to 0.70), Table 1. High latent correlation 
is indicative of convergent validity. A value of 0.7 could be considered high such that both 
MAX and AUC display strong convergent validity. Correlation between mobile thermography 
and standard thermography was also very high; 0.98 (0.94 to 1.00) for AUC and 0.90 (0.79 to 
0.97) for DDD, Latent correlation between LSCI and FLIR was 0.86 (0.74 to 0.97) for AUC and 
0.49 (0.29 to 0.66) for DDD. (Table 1).  
With the exception of some weak evidence of decreasing DDDT with increasing RCS (-0.15 
DDDT for a one point increase in RCS, on average, SE = 0.07) we found no evidence of 
correlation between the summary measures and RCS. 
Feasibility: Standard thermography was deemed to be more feasible than LSCI, In general, 
both techniques were deemed to be feasible (see discussion). The proportion of raters 
giving a score of 7 or above for ease of use (0=difficult–10=easy) was 50%for LSCI; 75%for 
standard thermography and 38%for mobile phone thermography. Ease of analysis was rated 
as 7 or above by 25% for LSCI and 50%for standard thermography. The number of centres 
preferring LSCI to thermography was 1 for acquiring and 1 for analysing images; preferring 
standard thermography 3 (acquiring) and 4 (analysing). The remaining centres showed no 
preference.  
Room temperature: When included as a covariate, temperature was not associated with any 
of the summary measures as measured by either LSCI or thermography. Additionally, the 
ICCs were not affected by the inclusion of temperature in the analysis. This does not mean 
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that a regulated room temperature is not important but that small changes in temperature 
are acceptable (supplementary Table S3).  
Edge effects: Moving from the thumb to the little finger, all of the AUC, MAX and GRAD 
trends were in the opposite direction for the two modalities, with a decrease for LSCI and an 
increase for thermography (supplementary Table S4). Both estimates for the DDD are 
positive, but this was attenuated for LSCI. This is consistent with an edge effect artificially 
producing lower values for the little fingers with LSCI. The cause of the edge effect was 
identified as the distribution of the light over the imaging area, due to LSCI being used at the 
upper limit of the suggested imaging distance in order to fit both hands into the imaging 
area. The data indicates that care must be taken to understand the variations over the field 
of view so that these can be accounted for; decreasing the field of view would minimise 
these results in future studies.  
 
DISCUSSION 
To date laser speckle imaging techniques and thermography have been insufficiently studied 
as outcome measures in clinical trials. Those studies in which they have been included show 
very little consistency in terms of protocol design (24, 36-38), choice of dynamic challenge 
and extracted outcome measures, making it difficult to compare results between studies or 
establish a standard protocol. The main finding of our study is that reliability of both LSCI 
and thermography were sufficiently high (AUC and MAX) for use as study outcome 
measures.  The reliability of MAXT was slightly superior to MAXL. Other than this, there were 
no substantive differences in reliability between the two techniques.  
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AUCM and DDDM showed adequate reliability for use as outcome measures. Moreover, there 
was strong correlation between mobile phone and standard thermography data. The mobile 
phone thermography was added at a late stage in this project (since it had only just come on 
the market). Our reason for including it was primarily for feasibility assessment. While it is 
clear that further work is required to validate mobile thermography, the performance in the 
present study is highly encouraging because as a low-cost tool it could potentially be readily 
available for widespread use amongst rheumatologists.   
 
Although not our primary objective, we examined differences between observers. 
Systematic differences between observers at different centres would not be particularly 
problematic for a multicentre randomised controlled trial (RCT), provided randomisation 
was stratified by centre. We note that this should be the default for any multicentre trial, 
since differences between centres may otherwise bias the estimated treatment effect. This 
is particularly true in small populations, since simple randomisation is less likely to produce 
balance within centres. Standardised training would reduce measurement variation across 
centres and centralised blinded extraction and analysis of LSCI data might also minimise 
variation by removing multi-observer differences in an RCT setting. Given the small sample 
size at each centre we are unable to determine whether truly systematic differences were 
observed. Ideally, a study to assess inter-observer reliability would involve participants 
having images analysed by all observers.   
 
Convergence between the techniques was shown to be very high for AUC and MAX 
(particularly for AUC). This provides evidence that the same underlying construct is being 
measured when using these summaries of response. Convergence appeared to be weaker 
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(although still moderate) for DDD. Convergence was weakest for GRAD which may reflect a 
lag between tissue re-perfusion (measured with LSCI) being translated into skin re-warming 
(measured using thermography) during the 2 minutes immediately following cold challenge. 
 
Since there is no gold standard to compare either imaging technique to, and we are 
comparing two techniques that measure perfusion by very different methods (skin 
temperature and a measure of red blood cell concentration and speed by light) it is possible 
to measure convergence between these techniques for validity (25). It would be unlikely for 
these two techniques to converge whilst also being poor measures since they would both 
have to be deficient in distinct but very specific ways so as to bring the erroneous 
observations into alignment. Therefore we can conclude in this instance that their 
convergence implies validity. 
 
The OMERACT review of 2003 (18) assessed the validity of several non-invasive techniques 
as possible objective outcome measures but none was deemed ready for use in clinical 
trials. These included nailfold capillaroscopy, a well-established diagnostic technique is now 
included in the diagnostic criteria (34) to differentiate primary and secondary Raynaud’s 
phenomenon. The microscopy technique allows visualisation of cutaneous capillaries at the 
nailbed and identification of structural change characteristic of SS.  This is not a substitute 
though for functional measures of flow (although functional flow and oxygenation have 
recently been reported). Plethysmography allows the change in vascular volume to be 
measured (i.e. detection of a pulse) in combination with cold challenge. The technique can 
measure full fields in the same ways as laser speckle but remains unvalidated. There was no 
relationship between the summary measures and the RCS on the day of the study visits, for 
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either LSCI or thermography. Patient-centred outcome measures are crucial for evaluating 
the effectiveness (rather than just the efficacy) of treatments. However, patient-centred 
outcomes often comprise more 'noise' compared to more objective measures of response, 
and therefore necessitate larger sample sizes to ensure adequate power in clinical trials. For 
small populations, there is therefore a tension between direct relevance to patients and 
feasibility of conducting a trial. One solution may be to power studies on the basis of 
objective measures such as those considered here, and to additionally (and consistently) 
report patient-centred outcomes to facilitate an eventual meta-analysis. Another might be 
to seek confirmatory evidence for the vasodilatory potential of candidate interventions 
using objective measures before proceeding to larger phase 3 clinical trials 
The relationship between two measures is limited by the reliability of each (39). While 
relative stability of RCS has been observed between baseline and follow-up in clinical 
trials/studies (38,40), there has been little work formally assessing its intra-individual 
reliability.  
Regarding feasibility, comments were made regarding LSCI and its sensitivity to movement, 
vibrations and lighting, indicating the importance of environmental conditions. For the 
mobile phone thermography, present limitations include battery life (LSCI and 
thermography were mains/long-life battery powered), fixed focussing distance and lack of 
analysis for video images, as well as mounting difficulties; however, if the mobile and 
standard thermography correlation can be replicated in future studies, these limitations 
may be acceptable in light of the lower cost and ambulatory (convenient) nature of the 
technique. When comparing feasibility of LSCI versus thermography, it should be noted that 
most centres were familiar with thermography but not LCSI, and that this may have 
influenced assessment of feasibility.  
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One limitation of the study was that we did not recruit the planned number of participants, 
due to a seventh centre not participating as planned. However, the study was designed to 
be robust to under-recruitment. Although the 95% CIs for our estimates are wider than they 
would have been had the target been met, we were still able to demonstrate good enough 
reliability and convergent validity of AUC and MAX, to observe differences indicative that 
that the performance of DDD was weaker, and to show that the performance of GRAD was 
relatively poor.  
 
In conclusion, our design was relatively pragmatic, with the aim of establishing the 
performance of the different techniques as they would be employed in a multicentre clinical 
trial. Our study successfully established a working group of tertiary-SSc centres, and 
together the group developed a consensus calibration and cold challenge protocol. The 
summary measures AUC and MAX both displayed good reliability and strong convergent 
validity. There was a possible advantage of thermography in relation to the reliability of 
MAX, although this was not definitive. We found evidence of edge effects when using LSCI 
although our summary measures appeared to be quite robust to these in relation to 
reliability, perhaps suggesting that these effects were fairly consistent (methods and results 
discussed in supplementary data). The study has also confirmed that small variations in 
room temperature are acceptable and that, subject to further validation, mobile phone 
cameras may be a suitable, affordable, highly portable alternative to more expensive 
standard imaging equipment (although mobile phones are battery operated and with less 
functionality [at present] than larger thermal cameras). The mobile phone data obtained in 
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this study will facilitate the design of future validation studies into mobile phone 
thermography-derived outcome measures. Although the design precluded formal 
assessment of inter-observer reliability there was a suggestion of systematic differences 
between the central observer and observers at some centres, highlighting the importance of 
image analysis training and potentially a role for centralised or automated image analysis. 
For multicentre RCTs, we would also recommend that where possible/appropriate, 
randomisation be stratified by centre to balance any centre effects and prevent bias.  
In summary LSCI and thermography should now be incorporated as secondary outcomes in 
upcoming treatment efficacy trials. This will allow an assessment of responsiveness to 
treatment as well as longitudinal validity. The present study leads us to recommend the 
summary measures AUC and MAX, measured using both thermography and LSCI (but 
especially using thermography), as suitable outcome measures for RCTs in SSc-related RP. 
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